C. Guyonneau

发表

213MO Primary endpoint analysis of a randomized phase II of darolutamide or capecitabine in patients with triple-negative androgen receptor-positive advanced breast cancer (UCBG3-06 START trial)

G. MacGrogan, H. Bonnefoi, O. Trédan, 2022, Annals of Oncology.